Unsere Kongressbeiträge

Kongressbeiträge 2018

M. Kresken, B. Körber-Irrgang, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Ergebnisse der PEG Resistenzstudie 2016 - Resistenzsituation im stationären Versorgungsbereich. 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Wien, 04. - 06. Oktober 2018: Poster Nr. 5.

pdf iconPoster

M. Kresken, B. Körber-Irrgang, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. Ergebnisse der PEG Resistenzstudie 2016 – Resistenzsituation bei Escherichia coli Urinisolaten gegenüber oral applizierbaren Antibiotika im ambulanten Versorgungsbereich. 26. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Wien, 04. - 06. Oktober 2018: Poster Nr. 6.

pdf icon

Poster

Michael Kresken, Barbara Körber-Irrgang, Gunnar Hischebeth, Achim Hoerauf, Nicole von Allmen, Michael Hogardt, Thomas A. Wichelhaus, Niels Pfennigwerth, Sören G. Gatermann. Occurrence of carbapenemase-producing strains among Enterobacterales urine isolates in three geographic areas in Germany. 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, April 21-24, 2018: P1072.

pdf iconPoster

Michael Kresken, Barbara Körber-Irrgang, Miriam Korte-Berwanger, Niels Pfennigwerth, Sören G. Gatermann. Dissemination of carbapenem-resistant, carbapenemase non-producing and carbapenemase-producing Pseudomonas aeruginosa in Germany. 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, April 21-24, 2018: O0124.

Oral Flash


Kongressbeiträge 2017

Kresken M, Körber-Irrgang B. In vitro pharmacodynamics of ceftobiprole against Staphylococcus aureus at concentrations corresponding to free drug levels achieved in human serum. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22-25, 2017: P1201.

pdf icon Poster


Kresken M, Körber-Irrgang B, Seifert H, and German Ceftolozan/Tazobactam Study Group.
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates non-susceptible to ceftazidime or meropenem. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22-25, 2017: P1235.

pdf icon Poster


Kresken M, Körber-Irrgang B, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy.
In vitro activity of mecillinam against urine isolates of Echerichia coli from outpatient departments in Germany. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 22-25, 2017: EV0561.

pdf icon Poster

 


Kongressbeiträge 2016

Kresken M, Körber-Irrgang B, Wallmann J, Kaspar H. GERMAP: Verbreitung von ESBL-bildenden und Chinolon-resistenten Escherichia-coli-Erregerisolaten in der Human- und Veterinärmedizin. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 26.

pdf icon

 Poster


Körber-Irrgang B, Pfeifer Y, Werner G, Kresken M.
  In vitro Aktivität von Cefoxitin gegenüber ESBL-produzierenden Escherichia-coli- und Klebsiella-pneumoniae-Isolaten aus dem Hospitalbereich. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 25.

pdf icon

 Poster


Körber-Irrgang B, Kresken M, Kniehl E, Becker A, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.
Epidemiologie und Antibiotika-Empfindlichkeit multiresistenter Gram-negativer (MRGN) Blutkulturisolate in Deutschland - Ergebnisse der Blutkulturstudie im Rahmen der PEG-Resistenzstudie 2013/14. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 12.

pdf icon

 Poster


Kresken M, Olzowy B, Havel M, Hafner D, Körber-Irrgang B, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.
Antibiotika-Empfindlichkeit bakterieller Erreger von Patienten mit HNO-Infektionen in der ambulanten Versorgung - Ergebnisse der PEG-Resistenzstudie 2013 und deren klinische Bedeutung. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 11.

pdf icon

 Poster


Körber-Irrgang B, Pfeifer Y, Werner G, Kresken M, Arbeitsgemeinschaft Empfindlichkeitsprüfungen und Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V.
ESBL-Bildung und Fluorchinolon-Resistenz bei Escherichia-coli- und Klebsiella-pneumoniae-Isolaten aus dem Hospitalbereich. 25. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Rostock, 06. - 08. Oktober 2016: Poster Nr. 10.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D für die Arbeitsgemeinschaft Empfindlichkeitsprüfungen & Resistenz der Paul-Ehrlich-Gesellschaft für Chemotherapie.
Verbreitung von multiresistenten Escherichia-coli-Urinisolaten in der ambulanten Patientenversorgung und In-vitro-Aktivität von Nitroxolin: Ergebnisse der PEG-Resistenzstudie 2013. 13. KIT, Würzburg, 15. - 18. Juni 2016: P-117.

pdf icon Poster


Körber-Irrgang B, von Müller L, Westenberger J, Hafner D, Herrmann M, Kresken M, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy.
In vitro activity of fidaxomicin and comparators against Clostridium difficile isolates obtained from community and hospitalized patients: results of the PEG study. 13. KIT, Würzburg, 15. - 18. Juni 2016: eP-009.

pdf icon Poster


Kresken M, Körber-Irrgang B, Seifert H, and German Ceftolozan/Tazobactam Study Group.
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. 13. KIT, Würzburg, 15. - 18. Juni 2016: eP-011.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D, and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy.
Multidrug resistance to oral antibiotics in Escherichia coli urine isolates from outpatients in Germany and in vitro activity of nitroxoline: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0077.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D, Kaase M, Pfeifer Y, Layer F, Klare I, Werner G, Seifert H,
and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of multidrug resistance among bacterial pathogens obtained from patients in hospitals and the role of tigecycline: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0326.

pdf icon Poster


Körber-Irrgang B, von Müller M, Westenberger J, Hafner D, Herrmann M, Kresken M and Working Party "Antimicrobial Resistance" of the Paul-Ehrlich-Society for Chemotherapy. Comparative susceptibilities of Clostridium difficile isolates to fidaxomicin obtained from community and hospitalized patients: results of the PEG 2013 study. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P0615.

pdf icon Poster


Kresken M, Körber-Irrgang B, Seifert H, and German Ceftolozan/Tazobactam Study Group.
In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany. 26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, April 9-12, 2016: P1314.

pdf icon Poster

 

Kongressbeiträge 2015


von Müller L, Herrmann M, Nimmesgern A, Körber-Irrgang B, Kresken M. Resistance profiling and ribotyping of Clostridium difficile isolates in Germany: Results of the PEG study 2013/2014. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 074/HYP.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D.
Susceptibility to ceftobiprole in blood and respiratory isolates collected from hospitalized patients prior to the introduction of this Group 5 cephalosporin: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 184/PRP.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D.
Susceptibility to multidrug-resistant pathogens from German hospitals to fosfomycin, 2013: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 188/PRP.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D. Occurrence of multidrug-resistant isolates (3MRGN, 4MRGN) among Gram-negative rods obtained from patients in German hospitals, 1995-2013: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 189/PRP.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D.
Occurrence of multidrug-resistant isolates  among Gram-positive pathogens obtained from patients in German hospitals, 1995-2013: results of the PEG study. Annual Meeting of DGHM, Münster, Deutschland, September 27-30 2015: 195/PRP.

pdf icon Poster


Kresken M, Körber-Irrgang B, Batista N, Besard V, Garcia-Castillo M, Cantón R, Pascual A, Kalka-Moll W, Schwarz R, Van Meensel B, Wisplinghoff H, Seifert H.
Susceptibility of Gram-negative pathogens isolated from patients with community-acquired urinary tract infections in three European Countries. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 25-28, 2015: P0800.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D.
In vitro activity of ceftobiprole against clinical isolates collected from blood and respiratory specimen of hospitalized patients: results of the PEG study. 25th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 25-28, 2015: P0831.

pdf icon Poster

 

Kongressbeiträge 2014

Körber-Irrgang B, Kresken M. Empfindlichkeit von Gram-negativen und Gram-positiven Harnwegserregern gegenüber Nitroxolin und Nitrofurantoin. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 19.

pdf icon Poster


Körber-Irrgang B, Kresken M für die Studiengruppe. Resistenzentwicklung von Streptococcus pneumoniae Isolaten gegenüber Doxycyclin, Erythromycin und Penicillin G in Deutschland, 2001-2010. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 11.

pdf icon Poster


Kresken M, Gatermann S. Aktivitäten des Deutschen Nationalen Antibiotika-Sensitivitätstestkomitee (NAK), 2012-2014. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 6.

pdf icon Poster


Kresken M, Wallmann J, Kaspar H, Kern W.V.
GERMAP - eine Intitiative von BVL, PEG und Infektiologie Freiburg. 24. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Weimar, 16. - 18. Oktober 2014: Poster Nr. 5.

pdf icon Poster

Körber-Irrgang B, Pfeifer Y, Wresch R, Kresken M. Occurrence of CTX-M-15 producing Escherichia coli belonging to clonal Group O25B:H4-ST131 in Germany, 2010. 66th DGHM, Dresden, Deutschland, Oktober 5-8, 2014: PRP54.

pdf icon Poster


Körber-Irrgang B, Kresken M.
Susceptibility of non Escherichia coli uropathogens to nitroxoline and the in vitro pH-activity relationship. 66th DGHM, Dresden, Deutschland, Oktober 5-8, 2014: PRP53.

pdf icon Poster


Kresken M, Körber-Irrgang B.
In vitro activity of ceftaroline against Staphyloccoccus aureus using concentrations achieved in humans determined by time-kill methodology. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10-13, 2014: eP179. 

pdf icon Poster


Kresken M, Körber-Irrgang B.
In vitro activity of nitroxoline against uropathogens other than Escherichia coli and impact of pH. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10-13, 2014: P0243.

pdf icon Poster


Körber-Irrgang B, Pfeifer Y, Wresch R and Kresken M.
Strains belonging to clonal Group O25B:H4-ST131 are widely disseminated among CTX-M-15 producing Escherichia coli recovered from in- and outpatients in Germany, 2010. 24th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, May 10-13, 2014: P1151.

pdf icon Poster


Kresken M, Körber-Irrgang B.
Lack of resistance to nitroxoline in Escherichia coli Urine isolates from outpatients. 12. KIT, Köln, 25. - 28. Juni 2014: Poster Nr. 007.

pdf icon Poster


Kresken M, Körber-Irrgang B.
Feasibility of the disc Diffusion methodology and the  M.I.C. Evaluator for susceptibility testing of ceftaroline against Staphylococcus aureus and ESBL-negative Enterobacteriaceae. Bad Honnef-Symposium, Königswinter, 13. - 14. April, 2014: Poster Nr. 2.

pdf icon Poster




Kongressbeiträge 2013


Körber-Irrgang B, Schedletzky H, Kaase M, Kresken M.
The Micronaut-S beta-lactamase VI test is a useful tool for phenotypic carbapenemase detection. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: DVP10.

pdf icon Poster


Körber-Irrgang B, Kresken M.
 Is nitroxoline an option for the treatment of uncomplicated urinary tract infections? Results of a German multicentre study on its in vitro activity against Escherichia coli urine isolates. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: FTP09.

pdf icon Poster


Körber-Irrgang B, Kresken M on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy.
Susceptibility of multidrug resistant organisms to tigecycline: results of the resistance surveillance study conducted by the Paul Ehrlich Society for Chemotherapy, 2010. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: NIP05.

pdf icon Poster


Körber-Irrgang B, Kresken M.
Evaluation of ceftaroline susceptibility in Gram-positive and Gram-negative pathogens from hospitalised skin infected patients: results of a surveillance study prior to its clinical use in Germany. Annual Meeting of DGHM, Rostock, Deutschland, September 22-25, 2013: NIP06.

pdf icon Poster


Kresken M, Körber-Irrgang B, Lass-Flörl C, Groll AH on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy.
Epidemiology of Candida species from sterile specimens in Germany and susceptibility to antifungal agents in vitro using the EUCAST method. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P985.

pdf icon Poster


Körber-Irrgang B and Kresken M on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. In vitro antibacterial activity of tigecycline against 434 multidrug resistant pathogens in Germany and a central European area, 2010. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1522.

pdf icon Poster


Kresken M, Körber-Irrgang B and Hafner D on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. Susceptibility of Gram-negative pathogens from hospitalized patients to colistin and fosfomycin in Germany 2010. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1531.

pdf icon Poster


Körber-Irrgang B, Schedletzky H, Kaase M and Kresken M. Phenotypic detection of carbapenemase-producing Gram-negative bacteria by using the MICRONAUT-S system for antimicrobial susceptibility testing. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1557.

pdf icon  Poster


Kresken M and Körber-Irrgang B on behalf of the German Ceftaroline Study Group. In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens obtained from hospitalised skin infected patients in Germany, 2011-2012. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1618.

pdf icon  Poster


Körber-Irrgang B and Kresken M. Frontline identification of bacterial isolates using the MALDI Biotyper-system during a resistance surveilllance study in a central European area, 2010. 23th European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, April 27-30, 2013: P1718.

pdf icon Poster

 

 

Kongressbeiträge 2012

Kresken M, Körber-Irrgang B. Resistenzhäufigkeit gegen Fosfomycin bei Escherichia-coli-Urinisolaten von Patientinnen aus dem ambulanten Versorgungsbereich - Ergebnisse der PEG Resistenzstudie aus dem Jahr 2010. 59. Jahreskongress der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe e.V., München, 9. - 13. Oktober 2012: Poster Nr: PO-Geb 07.02.

pdf icon Poster


Gatermann S, Kresken M.
Was ist NAK? 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 5.

pdf icon Poster


Kresken M, Körber-Irrgang B, Hafner D, Kaase M für die Arbeitsgemeinschaft Empfindlichkeitsprüfung & Resistenz
. Antibiotikaempfindlichkeit Carbapenem-nicht sensibler Enterobacteriaceae. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 6.

pdf icon Poster


Körber-Irrgang B, Klare I, Layer F, Werner G, Kresken M für die Arbeitsgemeinschaft Empfindlichkeitsprüfung & Resistenz.
Verbreitung nosokomialer Vancomycin-resistenter Enterokokken (VRE) in Deutschland und im mitteleuropäischen Raum. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 7.

pdf icon Poster


Körber-Irrgang B, Layer F, Klare I, Werner G, Kresken M für die Arbeitsgemeinschaft Empfindlichkeitsprüfung & Resistenz. Verbreitung von MRSA-Klonen bei hospitalisierten Patienten in Deutschland und im mitteleuropäischen Raum. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 8.

pdf icon Poster


Kresken M, Körber-Irrgang B, Ceftarolin-Studiengruppe. In-vitro-Aktivität von Ceftarolin gegen Gram-positive und Gram-negative Erreger von hospitalisierten Patienten mit komplizierten Haut/Weichgewebeinfektionen: Interimsanalyse der Ergebnisse einer multizentrischen Studie in Deutschland. 23. Jahrestagung der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V., Dresden, 11. - 13. Oktober 2012: Poster Nr. 18.

pdf icon Poster


Kresken M, Körber-Irrgang B. Antibiotika-Empfindlichkeit bei Pseudomonas-aeruginosa-Isolaten von Non-CF-Patienten aus dem ambulanten Versorgungsbereich - Ergebnisse der PEG Resistenzstudie 2010. 11. KIT, Köln, 25. - 28. April 2012: Poster Nr. 103.

pdf icon Poster


Körber-Irrgang B, Kresken M. Frontline-Identifizierung mit dem MALDI Biotyper - Erfahrungen aus der PEG Resistenzstudie. 11. KIT, Köln, 25. - 28. April 2012: Poster Nr. 110.

pdf icon Poster


Kresken M, Körber-Irrgang B on behalf of the Working Party Antimicrobial Resistance of the Paul Ehrlich Society of Chemotherapy. Occurrance of resistance to fosfomycin in urine isolates of E.coli collected from outpatients in Germany, 2010. 22th European Congress of Clinical Microbiology and Infectious Diseases, London, UK, March 31 - April 3, 2012: P1533. Clin Microbiol Infect 2012;18(issue s3):S412.

pdf icon Poster
pdf icon Abstract


Körber-Irrgang B, Zander E, Ritzenhoff A, Bauernfeind A, Schneider I, Kresken M.
Emergence and genetic environment of CTX-M enzymes produced by clinical Escherichia coli isolates in Germany, 2005-2009. 22th European Congress of Clinical Microbiology and Infectious Diseases, London, UK, March 31 - April 3, 2012: P1665. Clin Microbiol Infect 2012;18(issue s3):S460.

pdf icon Poster
pdf icon Abstract

 

 

Kongressbeiträge 2011

Kresken M, Hafner D. Trends in multidrug resistance among Escherichia coli and klebsiellae in Germany. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP01. International Journal of Medical Microbiology; 301S1:S16.

pdf icon Poster
pdf icon Abstract


Kresken M, Hafner D. No evidence of an overall increase in vancomycin MICs of German MRSA isolates between 2001 and 2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP02. International Journal of Medical Microbiology; 301S1:S17.

pdf icon Poster
pdf icon Abstract


Kresken M, Becker K, Seifert H, Körber-Irrgang B, von Eiff C, Löschmann PA. Susceptibility of major bacterial pathogens to tigecycline in Germany, 2004-2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP03. International Journal of Medical Microbiology; 301S1:S17.

pdf icon Poster
pdf icon Abstract


Kresken M, Körber-Irrgang B, Decker-Burgard S, Hafner D. Pharmacodynamics of three carbapenems considering the current susceptibility patterns of drug-resistant Gram-negative bacteria in Germany. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP04. International Journal of Medical Microbiology; 301S1:S18.

pdf icon Poster
pdf icon Abstract


Kresken M, Körber-Irrgang B. Antimicrobial susceptibility of ocular isolates in Germany, 2004-2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP07. International Journal of Medical Microbiology; 301S1:S18-9.

pdf icon Poster
pdf icon Abstract


Körber-Irrgang B, Bauernfeind A, Schneider I, Kresken M. Prevalence of CTX-M producing strains among Escherichia coli isolates from hospitalized patients in Germany, 2005-2009. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERP12. International Journal of Medical Microbiology; 301S1:S20.

pdf icon Poster
pdf icon Abstract


Kresken M, Hafner D. Susceptibility of Gram-negative pathogens to colistin and comparators in Germany. 63rd Annual Meeting of DGHM, Essen, Deutschland, September 25-28, 2011: ERV04. International Journal of Medical Microbiology; 301S1:S22.

pdf icon Abstract


Kresken M, Körber-Irrgang B on behalf of the Study Group. Feasibility of the Etest for susceptibility testing of doripenem against Gram-negative and Gram-positive bacteria using EUCAST breakpoints. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P754. Clin Microbiol Infect 2011;17(issue s4):S174.

pdf icon Poster
pdf icon Abstract
 

Kresken M, Körber-Irrgang B, Decker-Burgard S, Hafner D. Pharmacodynamics of three carbapenems against drug-resistant Gram-negative pathogens isolated from hospitalised patients in Germany using Monte Carlo Simulation. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P808. Clin Microbiol Infect 2011;17(issue s4):S192-3.

pdf icon Poster
pdf icon Abstract


Kresken M, Körber-Irrgang B on behalf of the German Ophthalmologic Study Group. Susceptibility to antibacterial agents in Germany amongst ocular isolates, 2004-2009: results of two laboratory surveillance studies. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P1097. Clin Microbiol Infect 2011;17(issue s4):S288.

pdf icon Poster
pdf icon Abstract


Kresken M, Becker K, Seifert H, Körber-Irrgang B, von Eiff C, Löschmann PA on behalf of the German Tigecycline Study Group. Tigecycline susceptibility trends in Germany among Gram-positive and Gram-negative pathogens recovered from wounds, the peritoneal cavity and blood. 21th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, May 7-10, 2011: P1123. Clin Microbiol Infect 2011;17(issue s4):S297.

pdf icon Poster
pdf icon Abstract


 

Kongressbeiträge 2010

Kresken M, Körber-Irrgang B for the Study Group. In vitro activity of carbapenems against German isolates of Pseudomonas aeruginosa and the Acinetobacter baumannii group and comparison of the Etest and broth microdilution method for doripenem susceptibility testing. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, USA, September 12-15, 2010: Abstract #D-742.

pdf icon Poster
 

Kresken M, Becker K, Seifert H, Körber-Irrgang B, Leitner E, von Eiff C for the Study Group. Tigecycline in vitro activity against multi-drug resistant pathogens from Germany. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, USA, September 12-15, 2010: Abstract #E-1599.

pdf icon Poster


Körber-Irrgang B, Lukas AM, Bauernfeind A, Schneider I, Kresken M.
 Shift towards CTX-M-15 as the predominant type of CTX-M Extended-Spectrum Beta-Lactamase produced by Escherichia coli isolates from hospitalized patients in Germany between 2005 and 2007. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, USA, September 12-15, 2010: Abstract #C2-678.

pdf icon Poster


Kresken M, Hafner D on behalf of the Working Party Antimicrobial Resistence of the Paul Ehrlich Society of Chemotherapy.
Susceptibility of Gram-negative pathogens to colistin and comparators in Germany, 2007. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P1638. Clin Microbiol Infect 2010;16(issue s2):S479. 

pdf icon Poster
pdf icon Abstract


Kresken M, Hafner D on behalf of the Working Party Antimicrobial Resistence of the Paul Ehrlich Society of Chemotherapy. Trends in multidrug resistance among Escherichia coli and klebsiellae in Germany, 1995-2007. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P1312. Clin Microbiol Infect 2010;16(issue s2):S370-1.

pdf icon Poster
pdf icon Abstract


Körber-Irrgang B, Röhrig A, Pletz M, Kresken M.
Prevalence of first-step parC mutans with amino acid alterations at resistance hot spots S79 and D83 among Streptococcus pneumoniae isolates in Germany. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P993. Clin Microbiol Infect 2010;16(issue s2):S269-70.

pdf icon Poster
pdf icon Abstract


Körber-Irrgang B, Kresken M.
In-vitro activity of daptomycin combined with other antimicrobial agents against Gram-negative bacteria. 20th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria, April 10-13, 2010: P646. Clin Microbiol Infect 2010;16(issue s2):S156-7.

pdf icon Poster
pdf icon Abstract

 

 

Kongressbeiträge 2009

Kresken M, Leitner E, Seifert H, Körber-Irrgang B, Peters G, von Eiff C for the Study Group. Susceptibility of bacterial isolates to tigecycline after the introduction of this Glycylcycline in Germany: Results of a second multicentre surveillance trial.
49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September 12-15, 2009: Abstract #C2-1955.

pdf icon Poster


Kresken M, Hafner D. Susceptibility of Gram-positive pathogens to Linezolid and other antibacterial agents in Germany, 2001-2007. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September 12-15, 2009: Abstract #C2-150.

pdf icon Poster


Körber-Irrgang B, Kresken M, Wetzstein H-G.
pH-Dependence of the activity of Pradofloxacin and four structual analogs against Escherichia coli and Staphylococcus aureus. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, USA, September 12-15, 2009: Abstract #E-1967.

pdf icon Poster


Kresken M, Körber-Irrgang B, Peters G, Leitner E, von Eiff C.
Trends of antimicrobial resistance among Staphylococci and Enterococci in Germany. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009: P1075. Clin Microbiol Infect 2009;15(issue s4):S286.

pdf icon Poster
pdf icon Abstract


Mutters R, Heizmann WR, Körber-Irrgang B, Leitner E, Kresken M.
Comparative in vitro activity of tigecycline against pathogens obtained from intensive care patients in Germany. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009: P1612. Clin Microbiol Infect 2009;15(issue s4):S457-8.

pdf icon Poster
pdf icon Abstract


Körber-Irrgang B, Kresken M.
In-vitro activity of daptomycin combined with other antimicrobial agents against Gram-positive cocci. 19th European Congress of Clinical Microbiology and Infectious Diseases, Helsinki, Finland, May 16-19, 2009: P1627. Clin Microbiol Infect 2009;15(issue s4):S462.

pdf icon Poster
pdf icon Abstract


Körber-Irrgang B, Kresken M.
In-vitro activity of daptomycin combined with other antimicrobial agents against Gram-positive cocci. 61st Annual Meeting of DGHM, Göttingen, Deutschland, September 20-23, 2009: PRP27.

pdf icon Poster


Kresken M, Leitner E, Seifert H, Körber-Irrgang B, Peters G, von Eiff C for the Study Group. In-vitro activity of tigecycline and comparators: a multicentre surveillance trial after the introduction of this glycylcycline in Germany. 61st Annual Meeting of DGHM, Göttingen, Deutschland, September 20-23, 2009.

pdf icon Poster

 

 

Kongressbeiträge 2008

Seifert H, Leitner E, Körber-Irrgang B, Kresken M. Comparative in vitro activity of tigecycline against clinical isolates of the Acinetobacter baumannii group: Results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program, 2005-2007. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / 46th Annual Meeting of the Infectious Diseases Society of America, Washington DC, USA, October 25-28, 2008: Abstract #C2-3870.

pdf icon Poster


Dahmen V, Georgieva L, Körber-Irrgang B, Kresken M, Bauernfeind A, Schneider I
Prevalence and molecular relatedness of Extended-Spectrum Beta-Lactamases (ESBL) produced by Escherichia coli isolated from hospitalized patients in Germany. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / 46th Annual Meeting of the Infectious Diseases Society of America, Washington DC, USA, October 25-28, 2008: Abstract #C2-3884.

pdf icon Poster


Kresken M, Körber-Irrgang B, Labischinski H, Stubbings W.
Effect of pH on the in vitro activity of finafloxacin against Gram-negative and Gram-positive bacteria. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy / 46th Annual Meeting of the Infectious Diseases Society of America, Washington DC, USA, October 25-28, 2008: Abstract #F1-2037.

pdf icon Poster


Kresken M, Brauers J, Strommenger B, Witte W.
Spread of MRSA clones in German hospitals and in vitro activity of tigecycline. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P1433. Clin Microbiol Infect 2008;14(issue s7):S409-10.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J.
German surveillance study on the in vitro activity of daptomycin against Gram-positive cocci. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P1723. Clin Microbiol Infect 2008;14(issue s7):S500-1.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J, Knips L, Leitner E, Menke A, Walter S, Weiher H.
Spread of tetracycline resistance genes among German isolates of Escherichia coli, Enterobacter cloacae, and Klebsiella pneumoniae and susceptibility to tigecycline. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P2038. Clin Microbiol Infect 2008;14(issue s7):S599-600.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J, Körber-Irrgang B. Resistance among isolates of Haemophilus influenzae to orally administered b-lactams and fluoroquinolones: results of a nationwide surveillance study in Germany, winter 2007. 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, April 19-22, 2008: P2054. Clin Microbiol Infect 2008;14(issue s7):S604-5.

pdf icon Poster
pdf icon Abstract

 

 

 

Kongressbeiträge 2007

Kresken M, Brauers J, Körber-Irrgang B. In-vitro-activity of fosfomycin against fluoroquinolone-resistant or extended-spectrum beta-lactamase-producing isolates of Escherichia coli. Int J Med Microbiol 2007;297(s1):39.

pdf icon Poster


Kresken M, Bagel S, Körber-Irrgang B, Wetzstein HG.
Comparative study on the pharmacodynamics of pradofloxacin (PRA) and marbofloxacin (MAR) against Staphylococcus intermedius in an In Vitro Pharmacokinetic Model of Infection (IVPM)
47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #A-18.

pdf icon Poster


Kresken M, Brauers J, Körber-Irrgang B, Menke A, Romfeld C.
In vitro activities of ceftobiprole (BPR) combined with amikacin (AMK) or levofloxacin (LVX) against Pseudomonas aeruginosa (PA) by time kill methodology. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #E-273.

pdf icon Poster


Kresken M, Brauers J, Prezelj A.
In vitro activity of LK-157, a novel tricyclic carbapenem beta-lactamase inhibitor. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #F1-338.

pdf icon Poster


Kresken M, Brauers J, Körber-Irrgang B, Labischinski H, Pelzer S.
Comparative in vitro activities of the novel antibacterial friulimicin and other antibacterial agents against selected aerobic Gram-positive bacteria. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, USA, September 17-20, 2007: Abstract #F1-1642.

pdf icon Poster


Kresken M, Brauers J, Halle E, Geiss H, Leitner E, Peters G, Seifert H.
Comparative in vitro activity of tigecycline against ICU- and non-ICU isolates of five clinically important Gram-negative pathogens: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Programme 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P666. Clin Microbiol Infect 2007;13(issue s1):S158-9.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J, Halle E, Geiss H, Leitner E, Peters G, Seifert H.
In vitro activity of tigecycline against Gram-positive and Gram-negative bacteria cultured from blood samples, wound swabs and intra-abdominal specimens: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Programme 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P1811. Clin Microbiol Infect 2007;13(issue s1):S517.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J.
Susceptibility of Gram-positive pathogens to daptomycin and other antimicrobial agents: first results from the DAPTOGERM Surveillance Study. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P1830. Clin Microbiol Infect 2007;13(issue s1):S523-4.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J, Halle E, Geiss H, Leitner E, Peters G, Seifert H.
Comparative in vitro activity of tigecycline against staphylococci and enterococci from patients on ICU- and non-ICU wards: results of the German T.E.S.T. Surveillance Programme 2005. 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 - April 3, 2007: P1831. Clin Microbiol Infect 2007;13(issue s1):S524.

pdf icon Poster
pdf icon Abstract

 

 

 

Kongressbeiträge 2006

Kresken M, Hafner D on behalf of the Working Group Antimicrobial Resistance of the Paul Ehrlich Society for Chemotherapy. Further increase of fluoroquinolone resistance among Escherichia coli isolates in a Central European Area. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006: P1396. Clin Microbiol Infect 2006;12(issue s4).

pdf icon Poster
pdf icon Abstract


Brauers J, Kresken M, Bagel S.
Comparative in vitro activities of telavancin and other antibacterial agents against selected Gram-positive bacteria. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006: P1582. Clin Microbiol Infect 2006;12(issue s4).

pdf icon Poster
pdf icon Abstract


Brauers J, Kresken M, Menke A, Orland A, Weiher H, Morrissey I.
Evaluation of daptomycin, vancomycin, teicoplanin and linezolid against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium utilizing in-vitro time-kill methodology. 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006: P1583. Clin Microbiol Infect 2006;12(issue s4).

pdf icon Poster
pdf icon Abstract


Kresken M, Hafner D. Working Group for Antimicrobial Resistance of the Paul Ehrlich Society for Chemotherapy. Susceptibilities of most prevalent Enterobacteriaceae species to ceftobiprole: results of the Antimicrobial Resistance Surveillance Study of the Paul Ehrlich Society for Chemotherapy, 2004. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-117.

pdf icon Poster


Kresken M, Brauers J.
In vitro activity of the novel antibacterial MCB3681 against selected Gram-positive and -negative bacteria compared to established antibiotics.
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #F1-1967.

pdf icon Poster


Seifert H, Brauers J, Leitner E, Kresken M.
Comparative in vitro activity of tigecycline against clinical Acinetobacter baumannii and Stenotrophomonas maltophilia isolates: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program 2005
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-748.

pdf icon Poster


Kresken M, Brauers J, Peters G, Leitner E.
Susceptibilities of three staphylococcal species to tigecycline and other drugs: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program 2005.46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-751.

pdf icon Poster


Geiss HK, Halle E, Brauers J, Leitner E, Kresken M.
In vitro activity of tigecycline against clinical isolates of Escherichia coli and four other major Enterobacteriaceae species: results of the German T.E.S.T. (G.-T.E.S.T.) Surveillance Program 2005
46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, USA, September 27-30, 2006: Abstract #E-752.

pdf icon Poster

 

 

 

Kongressbeiträge 2005

Kresken M, Hafner D on behalf of the Working Group Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Increase of resistance to nalidixic acid among four clinically important Enterobacteriaceae pathogens in three Central European countries. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005: P1464. Clin Microbiol Infect 2005;11(issue s2):S474.

pdf icon Poster
pdf icon Abstract


Kresken M, Heep M.
In vitro activity of ceftobiprole in combination with ciprofloxacin, levofloxacin, amikacin, and tobramycin against clinical isolates of Pseudomonas aeruginosa. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, December 16-19, 2005: Abstract #E-311.

pdf icon Poster

 

 

 

Kongressbeiträge 2004

Kresken M, Heep M, Hafner D. In-vitro activities of ceftobiprole (BAL9141), the active component of ceftobiprole (BAL5788), and seven other beta-lactams against selected strains of Pseudomonas aeruginosa susceptible or resistant to ceftazidime. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA, October 30 - November 2, 2004: Abstract #E-2022.

pdf icon Poster


Kresken M, Heep M, Wiegand I.
Gram-negative bacteria producing characterized beta-lactamases: in vitro activities of BAL 9141, the active component of prodrug BAL 5788, and comparators. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P536. Clin Microbiol Infect 2004;10(issue s3):S120-1.

pdf icon Poster
pdf icon Abstract


Kresken M, Hafner D, Allerberger F, Seifert H
on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Susceptibilities of clinical Acinetobacter baumannii and Stenotrophomonas maltophilia isolates to 14 antimicrobial agents: Results of the Antimicrobial Resistance Surveillance Study of the Paul Ehrlich Society for Chemotherapy, 2001. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1118. Clin Microbiol Infect 2004;10(issue s3):S304.

pdf icon Poster
pdf icon Abstract


Henrichfreise B, Bagel S, Kresken M, Sherwood K, Wiedemann B.
Detection of internationally spread multiresistant Streptococcus pneumoniae clones in Germany using Multilocus Sequence Typing. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1131. Clin Microbiol Infect 2004;10(issue s3):S308.

pdf icon Poster
pdf icon Abstract


Kresken M, Heep M.
In vitro activities of BAL9141, the active component of prodrug BAL5788, and seven other beta-lactam antimicrobial agents towards clinical isolates of 12 members of the family Enterobacteriaceae. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1209. Clin Microbiol Infect 2004;10(issue s3):S334.

pdf icon Poster
pdf icon Abstract


Wiedemann B, Kresken M, Bagel S.
Prevention of resistance development with Levofloxacin in epithelial lining fluid demonstrated by simulation of the concentration time curves in an in vitro model. 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004: P1808. Clin Microbiol Infect 2004;10(issue s3):S516.

pdf icon Poster
pdf icon Abstract

 

 

 

Kongressbeiträge 2003

Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA. Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of resistance to fluoroquinolones (ciprofloxacin) in clinical isolates of Escherichia coli in Germany, 1990-2001. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, September 14-17, 2003: Abstract #C2-96.

pdf icon Poster


Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA.
Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Susceptibility of Pseudomonas aeruginosa to antimicrobial agents in Germany, 2001. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, September 14-17, 2003: Abstract #C2-1961.

pdf icon Poster


Kresken M, Hafner D, Schmitz F-J, Wichelhaus TA
on behalf of the Working Group for Antimicrobial Resistance of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of mupirocin resistance in isolates of Staphylococcus aureus and Staphylococcus epidermidis in three Central European countries: Results of the Antimicrobial Resistance Surveillance Study of the Paul-Ehrlich-Society for Chemotherapy 2001. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1448. Clin Microbiol Infect 2003;9(issue s1):S352.

pdf icon Poster
pdf icon Abstract


Brauers J, Kresken M, Shah PM
on behalf of the German Linezolid Resistance Study Group. Surveillance of linezolid resistance in Germany. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1445. Clin Microbiol Infect 2003;9(issue s1):S351.

pdf icon Poster
pdf icon Abstract


Brauers J, Pfruender D, Kresken M.
Interpretive breakpoints for susceptibility testing of bacteria against penicillin G/sulbactam in the disk diffusion test according to the German DIN Standard 58940. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P473. Clin Microbiol Infect 2003;9(issue s1):S91.

pdf icon Poster
pdf icon Abstract


Henrichfreise B, Wiedemann B, Bagel S, Brauers J, Kresken M.
High prevalence of multiresistant penicillin-intermediate Streptococcus pneumoniae due to clonal spread in Germany, winter 2000/01. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1055. Clin Microbiol Infect 2003;9(issue s1):S247.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J, Bagel S.
Surveillance of antimicobial resistance in four major pathogens of community-acquired respiratory tract infections in Germany, 2002. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1575. Clin Microbiol Infect 2003;9(issue s1):S384-5.

pdf icon Poster
pdf icon Abstract


Bagel S, Brauers J, Kresken M.
Time-kill kinetics of clarithromycin, roxithromycin, and azithromycin against selected Streptococcus pneumoniae isolates compared with those of penicillin and moxifloxacin. 13th European Congress of Clinical Microbiology and Infectious Diseases, Glasgow, UK, May 10-13, 2003: P1013. Clin Microbiol Infect 2003;9(issue s1):S236.

pdf icon Poster
pdf icon Abstract


Kresken M, Brauers J, Bagel S, Henrichfreise B.
Was wissen wir über die Makrolidresistenz bei Streptococcus pneumoniae in Deutschland? Infection 2003;31(issue s1):86.

pdf icon Poster


Brauers J, Bagel S, Kresken M.
In-Vitro-Aktivität von Telithromycin und anderen Antibiotika gegenüber Streptococcus pneumoniae, Haemophilus influenzae und Moraxella catarrhalis in Deutschland. Infection 2003;31(issue s1):81.

pdf icon Poster

 

 

 

Kongressbeiträge 2002

Bagel S, Brauers J, Kresken M. In vitro activity of ABT-773 and six other antibacterial agents against recent community-acquired respiratory tract isolates: A German Multicenter Study. ICMAS-KO 6, Bologna, Italy, January 23-25: Abstract #2.11.

pdf icon Poster


Kresken M, Bagel S, Brauers J, Machka K.
In vitro activities of gemifloxacin and four other fluoroquinolones against contemporary respiratory tract pathogens recovered from outpatients in Germany. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 24-27, 2002: P1114. Clin Microbiol Infect 2002;8(issue s1):S252.

pdf icon Poster
pdf icon Abstract


Kresken M, Bagel S, Brauers J.
Comparative in vitro activity of faropenem, a new oral penem, against recent respiratory tract isolates recovered from outpatients in Germany. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 24-27, 2002:P1388. Clin Microbiol Infect 2002;8(issue s1):S326.

pdf icon Poster
pdf icon Abstract


Bagel S, Kresken M, Schmalreck A, Beck G, Pfründer D.
In vitro activity of new sulbactam combinations against aerobic and anaerobic bacteria: results of a German Multicentre Study. 12th European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy, April 24-27, 2002: P1439. Clin Microbiol Infect 2002;8(issue s1):S340.

pdf icon Poster
pdf icon Abstract


Henrichfreise B, Wiedemann B, Bagel S, Brauers J, Kresken M.
Geographical variation of macrolide-resistance in S. pneumoniae isolates from Germany. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, September 27-30, 2002: Abstract #C2-1979.

pdf icon Poster


Brauers J, Bagel S, Kresken M.
In vitro activity of telithromycin and other antibacterial agents against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in Germany. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, September 27-30, 2002: Abstract #E-1896.

pdf icon Poster


Kresken M, Bagel S, Brauers J, Henrichfreise B.
In vitro activity of the ketolide ABT-773 against macrolide-susceptible and -resistant isolates of Streptococcus pneumoniae in Germany. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California, USA, September 27-30, 2002: Abstract #E-1897.

pdf icon Poster

 

 

 

Kongressbeiträge 2001

Bagel S, Brauers J, Kresken M. In vitro activity of ABT-773 and six other antibacterial agents against recent community-acquired respiratory tract isolates: A German Multicenter Study. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, USA, September and December 2001: Abstract #1007.

pdf icon Poster

Kontakt

Antiinfectives Intelligence GmbH

Campus Hochschule Bonn-Rhein-Sieg

Von-Liebig-Straße 20
D-53359 Rheinbach

Fon +49 / 2226 / 908 911
Fax +49 / 2226 / 908 918

E-Mail senden
Weitere Informationen